Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Secondary Prevention Clear all
Completed Not applicable Interventional Results available

School Nurse-directed Secondary Obesity Prevention for Elementary School Children

NCT02029976
View directory record Official record
Conditions
Overweight, Obesity
Interventions
SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), Mailed monthly newsletters
Behavioral
Lead sponsor
Temple University
Other
Eligibility
8 Years to 12 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Amherst, Massachusetts • Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 3:33 PM EDT
Completed No phase listed Observational

Telestroke for Comprehensive Transient Ischemic Attack Care in Acute Stroke Ready Hospitals

NCT03724110
View directory record Official record
Conditions
Transient Ischemic Attack
Interventions
Telestroke
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Burnsville, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 21, 2026, 3:33 PM EDT
Active, not recruiting Phase 2 Interventional

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

NCT05364762
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School

NCT04478240
View directory record Official record
Conditions
Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions
PeerLearning.net
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
Not listed
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 3:33 PM EDT
Not yet recruiting Phase 2 Interventional

SAMe in Prevention of Oxaliplatin-associated Liver Injury

NCT06258525
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
Interventions
Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
Radiation · Dietary Supplement · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 3:33 PM EDT
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beginning Early and Assertive Treatment for Methamphetamine Use Disorder

NCT06033365
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
care navigation
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 21, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

NCT03654729
View directory record Official record
Conditions
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions
Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2 Interventional

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

NCT00108758
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis

NCT01508221
View directory record Official record
Conditions
Brain Metastasis
Interventions
Trental, Vitamin E
Drug · Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2 Interventional

Development of an Empowerment Intervention for Young Women Living With HIV

NCT01454921
View directory record Official record
Conditions
HIV
Interventions
Evolution: Young Women Taking Charge and Growing Stronger
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

NCT01760759
View directory record Official record
Conditions
HIV
Interventions
cell phone reminders, contingency management for adherence
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 21, 2026, 3:33 PM EDT
Terminated Phase 2 Interventional

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

NCT00040391
View directory record Official record
Conditions
Colorectal Neoplasms, Diarrhea
Interventions
Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
28
States / cities
Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional Results available

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

NCT01696760
View directory record Official record
Conditions
Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, Thromboembolism
Interventions
acetylsalicylic acid, enoxaparin, PCD
Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 21, 2026, 3:33 PM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional Results available

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

NCT01504711
View directory record Official record
Conditions
Gastrointestinal Cancer, Nausea Post Chemotherapy
Interventions
fosaprepitant dimeglumine
Drug
Lead sponsor
Philip Philip
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 21, 2026, 3:33 PM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 3:33 PM EDT
Recruiting No phase listed Observational

Optimizing Non-statin Agents for ASCVD

NCT07464574
View directory record Official record
Conditions
ASCVD Management
Interventions
Pharmacy Intern Counseling
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2Phase 3 Interventional

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

NCT00280943
View directory record Official record
Conditions
Hip Fractures, Osteoporosis
Interventions
Long-term care facilities in the intervention arm will receive education and feedback audit on performance
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255
View directory record Official record
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation

NCT00003883
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 21, 2026, 3:33 PM EDT
Completed Not applicable Interventional

Empowerment Intervention for Young Women - Phase I

NCT00891358
View directory record Official record
Conditions
HIV, Empowerment, HIV Infections
Interventions
Prevention Empowerment Intervention for Young Women
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 3:33 PM EDT